Actively Recruiting
Effect of Combined Endurance Training on ADL and Walking in COPD Patients
Led by Istituti Clinici Scientifici Maugeri SpA · Updated on 2025-05-30
36
Participants Needed
3
Research Sites
181 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with related exercise intolerance and marked disability due to symptoms such as dyspnea and fatigue. Effort intolerance and exercise-induced symptoms cause marked impairment in completing activities of daily living (ADL). Pulmonary rehabilitation (PR), which has exercise as a major component, is considered a key treatment in the management of COPD since PR is effective in improving exercise tolerance, exercise-induced dyspnea and fatigue, and health-related quality of life. Rehabilitation is also effective in improving the time required to perform ADLs, reducing symptoms and disability. Studies show that rehabilitation protocols with upper limb exercises added to lower limb training are able to give additional benefits in terms of effort tolerance (endurance time at the arm ergometer and oxygen consumption) and reduction of dyspnea at iso-load. The primary aim of this study is to evaluate whether the combined "arm and leg" training modality, compared to a gold standard protocol -involving only the lower limbs training- is more effective in improving ADL performance in terms of reduction of exercise time for a specific test (GLITTRE test).
CONDITIONS
Official Title
Effect of Combined Endurance Training on ADL and Walking in COPD Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- GOLD class 2-3 COPD
- Forced Expiratory Volume in the first second (FEV1) between 30% and 70% of the predicted value
- Ability to walk and climb stairs without assistance
- Stable clinical condition with pH greater than 7.35
You will not qualify if you...
- Chronic respiratory insufficiency requiring long-term oxygen therapy (LTOT)
- Severe orthopedic, neurological, or cardiological conditions
- Cognitive impairment
- Recent COPD exacerbation within 15 days requiring therapy change
- Presence of lung disease other than COPD
- Terminal illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Lumezzane
Lumezzane, Brescia, Italy, 25065
Actively Recruiting
2
ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Montescano
Montescano, Pavia, Italy, 27040
Not Yet Recruiting
3
ICS Maugeri IRCCS, Respiratory rehabilitation of the Institute of Tradate
Tradate, Varese, Italy, 21049
Completed
Research Team
M
Mara Paneroni, MSc, PT
CONTACT
T
Tiziana Bachetti, Pharm
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here